Danske Bank, Eitzen, Stolt-Nielsen: Nordic Equity Preview

The following companies may have unusual price changes in Nordic trading. Stock symbols are in parentheses and share prices are from the previous close.

The Stoxx Nordic 30 Index, the benchmark measure for the region, fell 0.2 percent to 7,708.99 in Stockholm.

The OMX Stockholm 30 Index slipped 0.1 percent, while the OMX Helsinki 25 Index gained 0.1 percent. Norway’s OBX Index decreased 0.5 percent. The Copenhagen 20 Index rose 0.2 percent.

Danske Bank A/S (DANSKE DC): Denmark’s largest lender may be interested in buying Allied Irish Banks Plc’s Northern Irish business, the Sunday Times reported, without citing anyone. The shares increased 2.6 percent to 138.7 kroner.

Diamyd Medical AB (DIAMB SS): The Swedish biotech company has dosed the first subject in a Phase II clinical trial in the U.S. evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain. The shares dropped 1.5 percent to 133 kronor.

Eitzen Chemical ASA (ECHEM NO): The Norwegian chemical- tanker owner said trading in the fourth quarter of 2010 was weaker than forecast, mainly because of lower activity in the regional trades. Continued increases in bunker prices had a negative effect on net timecharter rates, as stated in the third quarter report. The shares declined 1.8 percent to 1.66 kroner.

Kesko Oyj (KESBV FH): The Finnish retailer’s sales in December, excluding value-added tax, totaled 832.1 million euros ($1.1 billion), an increase of 7.9 percent, the group said in a statement. The shares slipped 0.5 percent to 34.33 euros.

Stolt-Nielsen Ltd. (SNI NO): The world’s largest operator of ocean-going chemical tankers employs armed guards and other anti-piracy measures on its ships at a monthly cost of $1 million, newspaper Dagens Naeringsliv reported, citing Chief Executive Officer Niels G. Stolt Nielsen. The shares fell 1.5 percent to 128.5 kroner.

To contact the reporter on this story: Giles Broom in Zurich at gbroom@bloomberg.net.

To contact the editor responsible for this story: David Merritt at dmerritt1@bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.